Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 9024 results

  1. Clindamycin for treating bacterial vaginosis in females aged 12 and older [TSID 12127]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  5. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MT604) (MIB268)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Surgical mesh for treatment of non-primary ventral hernias

    In development Reference number: GID-HTG10165 Expected publication date: TBC

    HealthTech guidance
    In development

  9. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Palbociclib with anti-HER2 therapy and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    Awaiting development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Budesonide orodispersible tablet for maintaining remission of eosinophilic oesophagitis in people 18 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Budesonide oral suspension for inducing and maintaining remission of eosinophilic oesophagitis in people 2 to 17 years [ID6761]

    Awaiting development Reference number: GID-TA12464 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    Awaiting development

  14. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Electrocautery cutting balloon treatment for pelviureteric junction obstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation